N-乙基-N-苯基脲 | 63099-20-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: N-乙基-N-苯基脲
• 英文名称: 3-bromo-ethyl propionate
• 英文别名: 4-bromomethylbutyrate；5-bromopentanoate；5-bromovalerate
• CAS: 63099-20-7
• 化学式: C₅H₈BrO₂
• 分子量: 180.021
• InChiKey: WNXNUPJZWYOKMW-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-乙基-N-苯基脲 在 四甲基氢氧化铵 作用下， 以 二甲基亚砜 为溶剂， 生成 delta-戊内酯
  参考文献：
  名称：

  Ring-closure reactions. 11. The activation parameters for the formation of four- to six-membered lactones from .omega.-bromoalkanoate ions. The role of the entropy factor in small- and common-ring formation

  摘要：

  DOI：

  10.1021/ja00470a032

文献信息

• Therapeutic compounds for treating dyslipidemic conditions
  申请人：Jones Brian A.

  公开号：US20050239769A1

  公开（公告）日：2005-10-27

  The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

  本发明涉及公式I的新型LXR配体及其药学上可接受的盐、酯和互变异构体，其在治疗脂质代谢异常症状，特别是低下的高密度脂蛋白胆固醇水平中有用。
• USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES
  申请人：Le Ridant Alain

  公开号：US20090298813A1

  公开（公告）日：2009-12-03

  Use of neuroprotective compounds in obtaining medicaments intended for the curative treatment of neurodegenerative disease and/or the prevention of the appearance of disorders ensuing from those diseases.

  使用神经保护化合物获得用于治疗神经退行性疾病和/或预防由这些疾病引起的障碍的药物。
• TRIAZABENZO (A)NAPHTHO(2,1,8-CDE) AZULENE COMPOUNDS.
  申请人：Brion Jean-Daniel

  公开号：US20100105666A1

  公开（公告）日：2010-04-29

  Compounds of formula (I): wherein: R 1 represents hydrogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )aminoalkyl or (C 1 -C 6 )hydroxyalkyl, R 2 represents hydrogen, or R 1 and R 2 , together with the carbon atoms carrying them, form a carbon-carbon bond, R 3 represents hydrogen, R 4 represents hydrogen, methyl or (C 3 -C 6 )alkyl, (C 1 -C 6 )aminoalkyl, (C 1 -C 6 )hydroxyalkyl, aryl-(C 1 -C 6 )alkyl or heterocycloalkyl-(C 1 -C 6 )alkyl, or R 3 and R 4 together with the carbon atoms carrying them, form a carbon-carbon bond, R 5 , R 6 , R 7 and R 8 represent hydrogen, or a pair of geminal substituents (R 5 and R 6 and/or R 7 and R 8 ) form an oxo, thioxo or imino group, R 9 represents hydrogen, halogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy, cyano, nitro, (C 1 -C 6 )polyhaloalkyl or optionally substituted amino, R 10 and R 11 represent hydrogen, halogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy, cyano, nitro, (C 1 -C 6 )polyhaloalkyl or optionally substituted amino, n represents an integer between 0 and 4 inclusive, m represents an integer between 0 and 2 inclusive, p represents an integer between 0 and 3 inclusive, X represents a group NR 12 , R 12 represents hydrogen, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, aryl-(C 1 -C 6 )alkyl or (C 1 -C 6 )polyhaloalkyl, their enantiomers, diastereoisomers and N-oxides, and also addition salts thereof with a pharmaceutically acceptable acid or base.

  分子式为（I）的化合物：其中：R1代表氢，（C1-C6）烷基，（C1-C6）氨基烷基或（C1-C6）羟基烷基；R2代表氢，或者R1和R2与携带它们的碳原子一起形成碳-碳键；R3代表氢；R4代表氢，甲基或（C3-C6）烷基，（C1-C6）氨基烷基，（C1-C6）羟基烷基，芳基-（C1-C6）烷基或杂环烷基-（C1-C6）烷基，或者R3和R4与携带它们的碳原子一起形成碳-碳键；R5、R6、R7和R8代表氢，或者一对近位取代基（R5和R6和/或R7和R8）形成氧代、硫代或亚氨基基团；R9代表氢，卤素，（C1-C6）烷基，（C1-C6）烷氧基，羟基，氰基，硝基，（C1-C6）多卤代烷基或可选取代的氨基；R10和R11代表氢，卤素，（C1-C6）烷基，（C1-C6）烷氧基，羟基，氰基，硝基，（C1-C6）多卤代烷基或可选取代的氨基；n表示0到4之间的整数；m表示0到2之间的整数；p表示0到3之间的整数；X代表NR12基团；R12代表氢，（C1-C6）烷基，（C2-C6）烯基，芳基-（C1-C6）烷基或（C1-C6）多卤代烷基，它们的对映异构体，顺反异构体和N-氧化物，以及与药学上可接受的酸或碱形成的加合盐。
• Ring-closure reactions. 11. The activation parameters for the formation of four- to six-membered lactones from .omega.-bromoalkanoate ions. The role of the entropy factor in small- and common-ring formation
  作者：Luigi Mandolini

  DOI：10.1021/ja00470a032

  日期：1978.1